Category Archives: Retinitis Pigmentosa

FIRATLI CLINIC ISTANBUL Retinitis Pigmentosa HeilungTunnelBlick) By: Osman Fıratlı … Continue reading →

Explaining Retinitis Pigmentosa, RP This is my best description I can give of retinitis pigmentosa to the onlooker or bystander, so to speak, if you will. I hope it helps and brings a better un... By: Sage Walsh … Continue reading →

IOWA CITY, Iowa Las Vegas casino mogul Steve Wynn will donate $25 million to the University of Iowa to accelerate the search for cures to rare eye diseases including the one that hampers his own vision, the school announced Thursday. The donation, to be paid over five years, will support the Institute for Vision Research, will be renamed in honor of the billionaire chairman and CEO of Wynn Resorts Ltd. The institute is a leader in genetic testing for eye disease and seeks to develop gene and stem cell therapies that could restore vision. Wynn, 71, has retinitis pigmentosa, a disease that affects one in 4,000 people and causes night blindness and weakness in peripheral vision. A fixture at Las Vegas galas, he's often seen leaning on an aide's arm at nighttime events. "As a person who knows firsthand what it is like to lose vision from a rare inherited eye disease, I want to do everything I can to help others who are similarly affected," he said in a statement. "I am thrilled by the pace of the scientific progress that has occurred in the past few years and I feel that the prospect of finding a cure is … Continue reading →

August 9, 2013 - South Atlantic League (SAL) Charleston RiverDogs CHARLESTON, SC - The Charleston RiverDogs have yet again left a large paw print on the fight against blindness and retinitis pigmentosa. During the Friday, August 9 contest against the Rome Braves at Joseph P. Riley, Jr. Park, RiverDogs General Manager Dave Echols will present a check for $20,000 to the Medical University of South Carolina (MUSC) Storm Eye Institute and its director, Dr. Lucian Del Priore. The donation comes from proceeds from the RiverDogs' 14th annual Kindness Beats Blindness Auction, the 10th Annual "Run Forrest Run" 5K, the 9thAnnual Hot Stove Banquet and the 8 th Annual Golf Outing. The Storm Eye Institute was selected as a result of RiverDogs President Mike Veeck's daughter, Rebecca, being diagnosed with retinitis pigmentosa, a group of inherited diseases causing retinal degeneration. Veeck and his wife, Libby, have dedicated themselves and most of their charitable efforts toward fighting blindness. "To work hand-in-hand with the Charleston community for the Storm Eye Institute is something we, as an organization, really look forward to every year," said Echols. "Seeing first-hand the effect this disease can have on a family adds a level of personality and affection … Continue reading →

Amarantus BioScience, Inc. (AMBS) today published a new blog post on The Chairmans Blog, written by the companys President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Amarantus President and CEO, Gerald Commissiong, blogs about the companys lead therapeutic program, MANF, and its orphan strategy in the ophthalmology field. He stresses, among other things, the successful company strategies hes seen; A prime example of a successful orphan strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis (SNY) in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe. Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/gerald-commissiong/2013-08/ophthalmology-manfs-orphan-strategy-coming-into-focus-in-retinitis-pigmentosa.html). About Amarantus BioScience, Inc. AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The … Continue reading →

SUNNYVALE, Calif., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced positive data for MANF in the degenerative disease known as Retinitis Pigmentosa ("RP"). The study concluded that Intravitreal injection of recombinant human MANF protein protects both rods and cones from retinal degeneration in an animal model of RP. RP is a degenerative disorder of the eye that affects roughly 100,000 people in the United States, meaning that it qualifies as an orphan disease under FDA guidelines. RP refers to a group of inherited diseases causing retinal degeneration. The cell-rich retina lines the back inside wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision as well as the degeneration in color perception and central vision; night blindness is one of the earliest and most frequent symptoms of RP. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from … Continue reading →